Clovis Oncology Announces Second Quarter 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Clovis Oncology (CLVS) Misses Q2 EPS by 6c
August 1, 2018 4:44 PM EDTClovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($1.94), $0.06 worse than the analyst estimate of ($1.88). Revenue for the quarter came in at $23.76 million versus the consensus estimate of $22.44 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More